logo-loader

Helix Biopharma shares rise despite posting $1.9 million loss in fiscal 2Q

Last updated: 17:40 18 Mar 2019 GMT, First published: 17:15 18 Mar 2019 GMT

Lab tech looking in a microscope
The biopharmaceutical company is currently conducting Phase I trials for its cancer-fighting drug

Helix Biopharma Corp (TSE:HBP) pushed ahead its research-and-development spending in the fiscal second quarter of 2019, despite recording a net loss of $1.9 million, according to financial results released Monday.

The company posted a net loss of $1.9 million, or $0.02 loss per common share, in the three months ended January 31, compared with a $2.6 million, or $0.03 loss, a year earlier.

Shares of Helix rose $0.03 on Monday to $0.54, a gain of 5.9%.

READ: Leap Therapeutics shares pop thanks to promising trial for cancer drug DKN-01

Helix, a clinical-stage biopharmaceutical company that is developing innovative therapies for cancer treatment, spent $1.3 million in research and development in fiscal 2Q and $2.3 million for the six-month period, the bulk of which was directed toward its L-DOS47 technology, which promises to act upon naturally-occurring substances in the human body to treat cancer.

The company spent $788,000 in the quarter, primarily on its Phase 1 clinical study in the US. It also conducting clinical studies in Poland, Ukraine and Hungary.

The Polish subsidiary, which is focusing on the V-DOS47 clinical program, spent $102,000 and $232,000 over the three-month period ending January 2019 and 2018, respectively. Grant-funding for the V-DOS4 program is the result of an agreement with the Polish National Centre for Research and Development.

Helix also reported a working capital deficiency of $2 million, a shareholders’ deficiency of $1.7 million and a deficit of $167 million. The company’s cash reserves of $306,000 are insufficient to meet its working capital and capital expenditures for the next 12 months, as well as its R&D expenditures, it reported.

--Contact Angela Harmantas at angela@proactiveinvestors.com

--Follow her on Twitter @AHarmantas

Cordiant Digital Infrastructure marks three years of strategic growth and...

Cordiant Digital Infrastructure Ltd (LSE:CORD) Chairman of Digital Infrastructure Steven Marshall and Chief Financial Officer Mark Tiner joined Steve Darling from Proactive to provide some insight on the company’s three-year anniversary since listing on the London Stock Market. The company...

1 hour, 40 minutes ago